|
06.11.2015 08:30:24
|
Active Biotech AB Interim report January - September 2015
Laquinimod
-
The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
-
The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington's disease, are proceeding as planned
Tasquinimod
-
The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ISI
-
Only commercial activities will be conducted from 2016
Financial summary
| MSEK | July - Sept. | Jan. - Sept. | Jan. - Dec. | |||||
| 2015 | 2014 | 2015 | 2014 | 2014 | ||||
| Net sales | 5.2 | 2.6 | 11.3 | 7.5 | 10.4 | |||
| Operating loss | -22.2 | -55.7 | -149.7 | -172.8 | -228.5 | |||
| Loss for the period | -23.4 | -56.6 | -152.7 | -174.5 | -231.5 | |||
| Loss per share, before and after dilution (SEK) | -0.26 | -0.76 | -1.70 | -2.33 | -3.02 | |||
| Cash and cash equivalents (at the end of the period) | 132.4 | 161.0 | 328.5 | |||||
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 00 |
The report is also available at www.activebiotech.com.
This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#1964749
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Active Biotech ABShsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Active Biotech ABShsmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.